Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

First Trust NYSE Arca Biotechnology Index Fund (FBT)

BATS BZX Real-Time Price
As of 12:48pm ET
 -2.40 / -2.96%
Today’s Change
Today|||52-Week Range

Investment Objective

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets (including investment borrowings) in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. It is non-diversified.

No recent news for First Trust NYSE Arca Biotechnology Index Fund.


1 month-26.15% 3 years+17.51%
3 months-25.53% 5 years+15.91%
1 year-25.06% Since inception+15.83%
Data through 02/06/2016

Quote Details

Previous close$81.17
Open day’s range77.61 – 79.86
Net asset value (NAV)81.25 (02/05/2016)
Daily volume9,546,846
Average volume (3 months)569,098
Data as of 12:48pm ET, 02/08/2016

Peer Comparisonvs. Health ETFs

Performance 5-yr return+15.91%+20.72%
Expense Gross exp ratio0.58%0.47%
Risk 5 year sharpe ratio0.761.06
Net assets$2.4B$1.4B
Average market cap$8.0B$36.5B
Average P/E22.422.4
Dividend / Share--0.22%


XLV Health Care Select Sector SPDR® Fund
VHT Vanguard Health Care Index Fund ETF Shar...
RYH Guggenheim S&P 500® Equal Weight Health...


Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
-- 3.82%
AMGN Amgen3.71%
BIIB Biogen3.68%
CRL Charles River Laboratories International Inc3.67%
TECH Bio-Techne Corp3.65%
GRFS Grifols SA3.58%
CELG Celgene3.58%
NKTR Nektar Therapeutics3.58%
MYGN Myriad Genetics Inc3.57%
Q Quintiles Transnational Holdings Inc3.53%

Partner Offers